See more : ABC arbitrage SA (ABCA.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Mesoblast Limited (MESO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mesoblast Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Energisa Mato Grosso – Distribuidora de Energia S/A (ENMT4.SA) Income Statement Analysis – Financial Results
- Alimentation Couche-Tard Inc. (ATD-B.TO) Income Statement Analysis – Financial Results
- FRISQ Holding AB (publ) (FRISQ.ST) Income Statement Analysis – Financial Results
- HDC HOLDINGS CO.,Ltd (012630.KS) Income Statement Analysis – Financial Results
- Beijing Shengtong Printing Co., Ltd (002599.SZ) Income Statement Analysis – Financial Results
Mesoblast Limited (MESO)
About Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.90M | 7.50M | 10.21M | 7.46M | 32.16M | 16.72M | 17.34M | 2.41M | 42.55M | 23.75M | 25.98M | 28.79M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Cost of Revenue | 41.07M | 54.92M | 63.57M | 85.73M | 81.50M | 75.17M | 5.51M | 12.07M | 29.76M | 23.78M | 25.43M | 21.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -35.17M | -47.42M | -53.36M | -78.28M | -49.34M | -58.45M | 11.83M | -9.65M | 12.79M | -35.00K | 546.00K | 7.52M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Gross Profit Ratio | 100.00% | -632.20% | -522.58% | -1,049.83% | -153.44% | -349.55% | 68.24% | -400.21% | 30.05% | -0.15% | 2.10% | 26.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 25.35M | 27.19M | 32.82M | 53.01M | 56.19M | 59.82M | 65.93M | 58.91M | 50.01M | 77.59M | 55.31M | 43.11M | 36.94M | 15.31M | 7.57M | 7.15M | 6.21M | 4.58M | 5.36M | 491.77K |
| General & Administrative | 23.63M | 25.37M | 27.21M | 30.87M | 25.61M | 21.63M | 21.91M | 23.01M | 22.50M | 36.17M | 26.56M | 30.73M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Selling & Marketing | 0.00 | 27.73M | 30.76M | 32.72M | 25.31M | 15.36M | 5.51M | 12.07M | 29.76M | 29.21M | 27.61M | 20.95M | 22.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.63M | 53.11M | 57.97M | 63.59M | 50.92M | 36.98M | 27.42M | 35.07M | 52.26M | 65.38M | 54.17M | 51.68M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Other Expenses | 0.00 | 0.00 | 30.76M | 32.65M | 25.23M | 15.48M | -1.31M | 10.53M | 25.92M | 122.00K | 16.49M | 15.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.98M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Cost & Expenses | 90.05M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Interest Income | 0.00 | 831.00K | 3.00K | 22.00K | 542.00K | 719.00K | 366.00K | 468.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 739.79K | 704.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 19.44M | 16.91M | 10.71M | 13.33M | 11.33M | 1.83M | 0.00 | 9.31M | 10.53M | 4.33M | 0.00 | 289.00 | 14.91K | 0.00 | 0.00 | 0.00 | 542.00 | 110.09K | 107.12K |
| Depreciation & Amortization | 1.90M | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M | 2.65M | 3.06M | 2.19M | 1.96M | 1.12M | 772.00K | 378.59K | 178.88K | 153.29K | 119.83K | 156.76K | 62.52K | 43.58K | 18.98K |
| EBITDA | -56.08M | -58.55M | -76.57M | -107.60M | -75.41M | -78.06M | -74.69M | -87.16M | -28.07M | -90.19M | -67.01M | -59.31M | -48.34M | 92.44M | -10.97M | -9.31M | -7.78M | -6.95M | -8.14M | -1.34M |
| EBITDA Ratio | -1,064.44% | -866.94% | -749.91% | -1,443.17% | -234.50% | -485.36% | -430.71% | -3,729.48% | -65.98% | -487.90% | -257.92% | -206.02% | -68.78% | 76.44% | -199,515.44% | -1,045.14% | -855.44% | -515.99% | -288.65% | -267.31% |
| Operating Income | -84.15M | -69.29M | -80.57M | -109.10M | -74.87M | -80.20M | -77.34M | -90.04M | -55.89M | -113.39M | -72.38M | -60.08M | -48.72M | 93.76M | -10.39M | -9.43M | -7.94M | -7.01M | -6.28M | -986.54K |
| Operating Income Ratio | -982.24% | -923.73% | -789.09% | -1,463.20% | -232.84% | -479.62% | -445.99% | -3,733.08% | -131.35% | -477.48% | -278.58% | -208.71% | -127.28% | 77.54% | -188,851.78% | -1,058.60% | -872.67% | -417.64% | -222.70% | -196.18% |
| Total Other Income/Expenses | -4.00M | -12.81M | -10.48M | 9.47M | -12.48M | -18.34M | 9.24M | -173.00K | -34.93M | -4.45M | -3.15M | 0.00 | -289.00 | -1.52M | -4.39M | -2.86M | -2.12M | -1.71M | -2.01M | -483.83K |
| Income Before Tax | -88.15M | -82.10M | -91.59M | -99.63M | -87.36M | -98.75M | -65.98M | -90.22M | -90.82M | -119.37M | -80.95M | -60.08M | -48.72M | 92.24M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Income Before Tax Ratio | -1,493.51% | -1,094.53% | -896.93% | -1,336.24% | -271.66% | -590.56% | -380.47% | -3,740.26% | -213.46% | -502.64% | -311.60% | -208.71% | -127.28% | 76.28% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| Income Tax Expense | 191.00K | -212.00K | -239.00K | -819.00K | -9.42M | -8.96M | -30.69M | -13.40M | -86.69M | 6.10M | 5.00K | 1.59M | 22.42M | 1.63M | -739.79K | 0.00 | 0.00 | -1.71M | -1.79M | -269.59K |
| Net Income | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M | -89.80M | -35.29M | -76.82M | -4.13M | -119.37M | -80.96M | -61.66M | -71.15M | 90.61M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Net Income Ratio | -1,490.27% | -1,091.71% | -894.59% | -1,325.25% | -242.38% | -537.01% | -203.51% | -3,184.70% | -9.70% | -502.64% | -311.62% | -214.21% | -185.86% | 74.93% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| EPS | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.41 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.39 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 986.70M | 739.04M | 648.78M | 605.07M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
| Weighted Avg Shares Out (Dil) | 986.70M | 739.04M | 648.90M | 605.09M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
FDA's Office Agrees On 12-Month Reduction In Pain As Primary Endpoint For Mesoblast's Back Pain Study
Mesoblast Limited (NASDAQ: MESO) received feedback from the FDA's Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients. The trial is assessing rexlemestrocel-L in patients with chronic low back pain (CLBP) due to degenerative disc disease...
FDA's OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received feedback from the US Food & Drug Administration's (FDA) Office of Tissues and...
Down 35.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Mesoblast Limited (MESO)
The heavy selling pressure might have exhausted for Mesoblast Limited (MESO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
Update on Novartis Agreement
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing. Mesoblast...
Mesoblast's Heart Failure Candidate Shows Treatment Benefit In High-Risk Patients
Mesoblast Limited (NASDAQ: MESO) announced new analyses from the landmark DREAM-HF Phase 3 trial of rexlemestrocel-L in HFrEF patients with diabetes and/or ischemia who are at high risk of cardiovascular mortality, heart attacks, or strokes. In recent guidance to Mesoblast, FDA confirmed that...
Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
Endpoint in Line with FDA Guidance on Key Outcomes in High-Risk Patients and with Pharma Industry Drugs Approved for Cardiovascular Risk Reduction in Diabetes Endpoint in Line with FDA Guidance on Key Outcomes in High-Risk Patients and with Pharma Industry...
Mesoblast Limited (MESO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for...
Operational Highlights and Financial Results for the Period Ended September 30, 2021
NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the first quarter ended September 30, 2021.
Mesoblast Corporate Update and Financial Results Webcast
NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the first quarter ended September 30, 2021.
Source: https://incomestatements.info
Category: Stock Reports